Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03993873
Title	Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1)
Acronym	SHIELD-1
Recruitment	Active, not recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Turning Point Therapeutics, Inc.
Indications	lung non-small cell carcinoma stomach cancer gastroesophageal junction adenocarcinoma hepatocellular carcinoma Advanced Solid Tumor
Therapies	Elzovantinib
Age Groups:	adult \| senior
Covered Countries	USA \| FRA \| ESP